This panel discussion brings together key perspectives on the interplay between heart, metabolic, and renal health, highlighting how SGLT2 inhibitor and DPP-4 inhibitor combinations are reshaping outcomes in patients with diabetes and associated co-morbidities. The session focuses on real-world evidence, patient selection, cardio-renal protection, and practical treatment strategies to achieve comprehensive cardio-renal-metabolic benefits in routine clinical practice.